Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vardenafil hydrochloride trihydrate (BAY38-9456) 是一种新型 PDE 抑制剂,对 PDE5 和 PDE1 的 IC50 分别为 0.7 和 180 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 185 | 现货 | ||
5 mg | ¥ 412 | 现货 | ||
10 mg | ¥ 593 | 现货 | ||
25 mg | ¥ 1,130 | 现货 | ||
50 mg | ¥ 1,960 | 现货 | ||
100 mg | ¥ 3,150 | 现货 | ||
200 mg | ¥ 4,530 | 现货 | ||
500 mg | ¥ 6,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 557 | 现货 |
产品描述 | Vardenafil hydrochloride trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively. |
靶点活性 | PDE5:0.7 nM, PDE1:180 nM |
体外活性 | Vardenafil specifically inhibits the hydrolysis of cGMP by PDE5 with an IC50 of 0.7 nM (6.6 nM). Vardenafil significantly enhances the SNP-induced relaxation of human trabecular smooth muscle at 3 nM (10 nM). Vardenafil also significantly potentiates both ACh-induced and transmural electrical stimulation-induced relaxation of trabecular smooth muscle. Vardenafil (100 mM) increases cyclic GMP levels in rat hippocampal slices. Vardenafil, tadalafil, and Sildenafil each competitively inhibit cGMP hydrolysis by phosphodiesterase-5 (PDE5), thereby fostering cGMP accumulation and relaxation of vascular smooth muscle. |
体内活性 | Vardenafil dose-dependently potentiates erectile responses to intravenously administered sodium nitroprusside in rabbit. Vardenafil (3 mg/kg, p.o.) results in an improved object discrimination performance in rats. Vardenafil (30 mg/L, p.o.) increases both iNOS and proliferating cell nuclear antigen expression (SM cell replication) in rats, with normalization of the dynamic infusion cavernosometry drop rate and SM/collagen ratio. Vardenafil induces powerful preconditioning-like cardioprotective effect against ischemia/reperfusion injury through the opening of mitochondrial K(ATP) channels in the heart of rabbit. Vardenafil protects the ischemic myocardium against reperfusion injury through a mechanism dependent on mitochondrial K(ATP) channel opening. |
别名 | Vardenafil HCl Trihydrate, BAY38-9456, 盐酸瓦地那非三水合物 |
分子量 | 579.11 |
分子式 | C23H32N6O4S·HCl·3H2O |
CAS No. | 330808-88-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (160.6 mM)
H2O: 10 mg/mL (17.27 mM)
Ethanol: 16 mg/mL (27.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O / Ethanol | 1 mM | 1.7268 mL | 8.6339 mL | 17.2679 mL | 43.1697 mL |
5 mM | 0.3454 mL | 1.7268 mL | 3.4536 mL | 8.6339 mL | |
10 mM | 0.1727 mL | 0.8634 mL | 1.7268 mL | 4.317 mL | |
DMSO / Ethanol | 20 mM | 0.0863 mL | 0.4317 mL | 0.8634 mL | 2.1585 mL |
DMSO | 50 mM | 0.0345 mL | 0.1727 mL | 0.3454 mL | 0.8634 mL |
100 mM | 0.0173 mL | 0.0863 mL | 0.1727 mL | 0.4317 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vardenafil hydrochloride trihydrate 330808-88-3 Metabolism PDE Vardenafil HCl hepatitis Zucker diabetic fatty (ZDF) rats Inhibitor dysfunction erectile smooth Vardenafil HCl Trihydrate Vardenafil hydrochloride muscle Endogenous Metabolite pharmacokinetics selective BAY38-9456 inhibit Vardenafil Hydrochloride erectile dysfunction Vardenafil hydrochloride Trihydrate impotence Vardenafil diabetes Phosphodiesterase (PDE) stimulation cGMP 盐酸瓦地那非三水合物 inhibitor